BN80927 in Patients With Advanced Malignant Solid Tumors
NCT01435096
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
56
Enrollment
INDUSTRY
Sponsor class
Conditions
Malignant Solid Tumour
Interventions
DRUG:
BN80927
Sponsor
Ipsen